Evicenter
MarkdownMedical informationP&T meetings
Ficerafusp alfa (BCA101)

First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab

Last updated
135 sources

Economic information and modeling reportBudget impact model

Budget impact model discussion

3 evidence topics · 12 sources

Summary

Task force good-practice guidance on budget impact analysis lists the key elements of a budget impact analysis as the size of the eligible population, the current and expected treatment mix, the cost of each mix, and changes in condition-related costs, and recommends the perspective of the specific decision maker, data from the decision maker's own population where possible, and presentation as a series of scenario analyses. For ficerafusp alfa, two inputs are not yet available: a price, and efficacy from randomized evidence. Results reported to date come from a nonrandomized, open-label phase 1/1b trial, and Bicara expects an interim analysis of the randomized FORTIFI-HN01 trial in mid-2027.

The population inputs in this report differ by source and are candidates for scenario ranges. The estimated HPV-negative share of recurrent or metastatic disease is 80% in Bicara's Form 10-K; in a U.S. real-world first-line cohort, 60.4% had non-HPV associated disease and 7.0% had unknown HPV status or primary site, and in a U.S. real-world cohort of first-line pembrolizumab recipients, 258 participants (39.9%) were HPV-negative and 155 (24.0%) equivocal or unknown. Bicara states that up to 30% of patients develop a recurrence or metastases after initial treatment for advanced HNSCC; Hanna et al. (2026) state that approximately 50% of those with locally advanced HNSCC have recurrence or metastasis after initial therapy; of 2,207 U.S. participants, 32.7%. Because the pivotal population requires PD-L1 CPS ≥1, testing rates bear on the identifiable population: of 2,207 U.S. participants, 32.7% received PD-L1 testing before first-line therapy and 50.0% were never tested.

On costs, pembrolizumab is given in both arms of FORTIFI-HN01, and ficerafusp alfa is given weekly until disease progression or unacceptable toxicity, while pembrolizumab is given for up to 35 cycles. FORTIFI-FLEX is evaluating a 12-week loading phase of 1500 mg weekly followed by 2250 mg every 3 weeks, which would change the number of administrations if adopted. Bicara states that third-party payers “may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug or a less expensive therapy is available.”